- Home
- SKYE vs BRW Comparison
SKYE vs BRW Comparison
Compare SKYE & BRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- BRW
- Stock Information
- Founded
- SKYE 2012
- BRW 1987
- Country
- SKYE United States
- BRW United States
- Employees
- SKYE N/A
- BRW N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- BRW Trusts Except Educational Religious and Charitable
- Sector
- SKYE Health Care
- BRW Finance
- Exchange
- SKYE Nasdaq
- BRW Nasdaq
- Market Cap
- SKYE 73.4M
- BRW 333.0M
- IPO Year
- SKYE N/A
- BRW N/A
- Fundamental
- Price
- SKYE $4.61
- BRW $8.12
- Analyst Decision
- SKYE Buy
- BRW
- Analyst Count
- SKYE 6
- BRW 0
- Target Price
- SKYE $16.60
- BRW N/A
- AVG Volume (30 Days)
- SKYE 2.0M
- BRW 222.1K
- Earning Date
- SKYE 08-08-2025
- BRW 01-01-0001
- Dividend Yield
- SKYE N/A
- BRW 15.59%
- EPS Growth
- SKYE N/A
- BRW N/A
- EPS
- SKYE N/A
- BRW N/A
- Revenue
- SKYE N/A
- BRW N/A
- Revenue This Year
- SKYE N/A
- BRW N/A
- Revenue Next Year
- SKYE N/A
- BRW N/A
- P/E Ratio
- SKYE N/A
- BRW N/A
- Revenue Growth
- SKYE N/A
- BRW N/A
- 52 Week Low
- SKYE $1.14
- BRW $7.15
- 52 Week High
- SKYE $7.60
- BRW $8.30
- Technical
- Relative Strength Index (RSI)
- SKYE 74.70
- BRW 71.83
- Support Level
- SKYE $3.41
- BRW $7.85
- Resistance Level
- SKYE $5.75
- BRW $8.18
- Average True Range (ATR)
- SKYE 0.60
- BRW 0.09
- MACD
- SKYE 0.17
- BRW 0.02
- Stochastic Oscillator
- SKYE 69.27
- BRW 87.18
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.